Do analysts prefer ALDX or EGRX?

Aldeyra Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 212.50%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ALDX or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Eagle Pharmaceuticals N/A N/A N/A

Do analysts prefer EGRX or EDSA?

Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 29.48%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EGRX or EDSA more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Edesa Biotech N/A -286.52% -75.36%

Do analysts rate EGRX or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate EGRX or IBIO?

iBio has a consensus price target of $4.75, suggesting a potential upside of 146.11%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Eagle Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 iBio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.17

Which has higher valuation & earnings, EGRX or IBIO?

Eagle Pharmaceuticals has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eagle Pharmaceuticals $257.55M 0.03 $35.64M $1.18 0.44 iBio $400K 239.71 -$18.38M -$0.58 N/A

Is EGRX or IBIO more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A iBio N/A -53.86% -46.48%

Do analysts rate EGRX or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EGRX or TELO more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Telomir Pharmaceuticals N/A -201.23% -172.71%

Eagle Pharmaceuticals (EGRX) Competitors

$0.52 -0.13 (-19.23%)

As of 06/4/2026 03:23 PM Eastern

Compare

EGRX vs. ALDX, EDSA, ICCC, IBIO, and TELO

Should you buy Eagle Pharmaceuticals stock or one of its competitors? MarketBeat compares Eagle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eagle Pharmaceuticals include Aldeyra Therapeutics (ALDX), Edesa Biotech (EDSA), ImmuCell (ICCC), iBio (IBIO), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does Eagle Pharmaceuticals compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Eagle Pharmaceuticals' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Eagle Pharmaceuticals	N/A	N/A	N/A

Aldeyra Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Aldeyra Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 212.50%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aldeyra Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44

In the previous week, Aldeyra Therapeutics had 7 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 7 mentions for Aldeyra Therapeutics and 0 mentions for Eagle Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 0.20 beat Eagle Pharmaceuticals' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
Eagle Pharmaceuticals	Neutral

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats Aldeyra Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Edesa Biotech?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Eagle Pharmaceuticals has higher revenue and earnings than Edesa Biotech. Edesa Biotech is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Eagle Pharmaceuticals' return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Edesa Biotech	N/A	-286.52%	-75.36%

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edesa Biotech has a consensus target price of $5.00, indicating a potential downside of 29.48%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Edesa Biotech is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 beat Edesa Biotech's score of -0.52 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Edesa Biotech	Negative

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Summary

Eagle Pharmaceuticals beats Edesa Biotech on 9 of the 13 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to ImmuCell?

Eagle Pharmaceuticals (NASDAQ:EGRX) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell's average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
ImmuCell	Very Positive

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 13.5% of ImmuCell shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44
ImmuCell	$27.64M	3.23	-$1.04M	-$0.06	N/A

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Eagle Pharmaceuticals has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. Eagle Pharmaceuticals' return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
ImmuCell	-1.82%	-1.88%	-1.22%

Summary

Eagle Pharmaceuticals beats ImmuCell on 10 of the 13 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to iBio?

Eagle Pharmaceuticals (NASDAQ:EGRX) and iBio (NASDAQ:IBIO) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, iBio had 4 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 4 mentions for iBio and 0 mentions for Eagle Pharmaceuticals. iBio's average media sentiment score of 0.37 beat Eagle Pharmaceuticals' score of 0.00 indicating that iBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
iBio	Neutral

Eagle Pharmaceuticals has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44
iBio	$400K	239.71	-$18.38M	-$0.58	N/A

Eagle Pharmaceuticals' return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
iBio	N/A	-53.86%	-46.48%

iBio has a consensus price target of $4.75, suggesting a potential upside of 146.11%. Given iBio's stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
iBio	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.17

Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, iBio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of iBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Eagle Pharmaceuticals and iBio tied by winning 8 of the 16 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Telomir Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eagle Pharmaceuticals' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Eagle Pharmaceuticals has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.44
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for Telomir Pharmaceuticals and 0 mentions for Eagle Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Telomir Pharmaceuticals	Very Positive

Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

Summary

Eagle Pharmaceuticals beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.82M	$998.88M	$6.30B	$12.43B
Dividend Yield	N/A	4.84%	2.69%	5.33%
P/E Ratio	0.44	1.49	23.79	24.34
Price / Sales	0.03	131.96	531.86	113.60
Price / Cash	0.40	20.06	41.39	55.53
Price / Book	N/A	8.12	10.04	6.72
Net Income	$35.64M	-$3.91M	$3.56B	$337.03M
7 Day Performance	-8.70%	-1.71%	-1.00%	-0.13%
1 Month Performance	N/A	66.40%	2.25%	3.76%
1 Year Performance	-76.14%	110.64%	29.12%	34.36%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.53 -19.2%	N/A	-75.0%	$6.82M	$257.55M	0.44	100
ALDX Aldeyra Therapeutics	3.3373 of 5 stars	$1.78 +14.8%	$5.50 +209.0%	-28.7%	$93.50M	N/A	N/A	10	High Trading Volume
EDSA Edesa Biotech	1.8211 of 5 stars	$9.70 -7.3%	$5.00 -48.5%	+263.6%	$93.01M	N/A	N/A	20
ICCC ImmuCell	0.9713 of 5 stars	$10.50 +3.8%	N/A	+46.2%	$91.55M	$27.64M	N/A	70	Short Interest Decrease High Trading Volume
IBIO iBio	3.9171 of 5 stars	$1.82 -1.1%	$4.75 +161.0%	N/A	$91.41M	$400K	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. ALDX, EDSA, ICCC, IBIO, and TELO

How does Eagle Pharmaceuticals compare to Aldeyra Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to Edesa Biotech?

Summary

How does Eagle Pharmaceuticals compare to ImmuCell?

Summary

How does Eagle Pharmaceuticals compare to iBio?

Summary

How does Eagle Pharmaceuticals compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. ALDX, EDSA, ICCC, IBIO, and TELO

How does Eagle Pharmaceuticals compare to Aldeyra Therapeutics?

Is ALDX or EGRX more profitable?

Which has more volatility and risk, ALDX or EGRX?

Do analysts prefer ALDX or EGRX?

Which has stronger valuation and earnings, ALDX or EGRX?

Does the media favor ALDX or EGRX?

Do institutionals and insiders have more ownership in ALDX or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Edesa Biotech?

Which has better valuation & earnings, EGRX or EDSA?

Is EGRX or EDSA more profitable?

Do institutionals and insiders believe in EGRX or EDSA?

Do analysts prefer EGRX or EDSA?

Does the media prefer EGRX or EDSA?

Which has more risk and volatility, EGRX or EDSA?

Summary

How does Eagle Pharmaceuticals compare to ImmuCell?

Do analysts rate EGRX or ICCC?

Does the media prefer EGRX or ICCC?

Do institutionals & insiders hold more shares of EGRX or ICCC?

Which has higher earnings & valuation, EGRX or ICCC?

Which has more risk & volatility, EGRX or ICCC?

Is EGRX or ICCC more profitable?

Summary

How does Eagle Pharmaceuticals compare to iBio?

Does the media refer more to EGRX or IBIO?

Which has higher valuation & earnings, EGRX or IBIO?

Is EGRX or IBIO more profitable?

Do analysts rate EGRX or IBIO?

Which has more risk and volatility, EGRX or IBIO?

Do institutionals and insiders have more ownership in EGRX or IBIO?

Summary

How does Eagle Pharmaceuticals compare to Telomir Pharmaceuticals?

Do analysts rate EGRX or TELO?

Is EGRX or TELO more profitable?

Do institutionals & insiders hold more shares of EGRX or TELO?

Which has stronger earnings & valuation, EGRX or TELO?

Does the media refer more to EGRX or TELO?

Which has more risk & volatility, EGRX or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools